Davesomeran is an mRNA vaccine in combination with the Moderna COVID-19 vaccine to prevent infection from the Omicron variant of the SARS-CoV-2 virus in people 6 years old or older. Similar to the previous Moderna COVID-19 vaccine, Moderna Bivalent vaccine encodes the full-length pre-fusion stabilized spike (S) protein to elicit an immune response.
- Mechanism
- Curator reviewed · 5 references
The Moderna Bivalent vaccine contains 2 ingredients: davesomeran and elasomeran. They both contains synthetic nucleoside-modified messenger RNA (mRNA) encapsulated in Lipid nanoparticle (LNP) encoding the full-length, pre-fusion stabilized spike protein (S) of SARS-CoV-2, although davesomeran's mRNA specifically targets the BA.4/5 Omicron variants with the L452R and F486V mutations in the S protein. The S protein is a major membrane glycoprotein that can bind to the ACE2 receptor in targeted host cells. Due to its location, the S protein is the main target for most mRNA vaccines due to its immunogenicity.
- Primary indication
- Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is a mixture of 2 mRNA vaccines, davesomeran and elasomeran, and is indicated for active immunization against COVID-19.Curator reviewed · 5 structured indications
- First approval
- Canada, 2023
- Code names
- CX-034476 Omicron (BA.4/BA.5)
Resolves to
What you can answer from here — as of March 03, 2026
Which other approved drugs treat the same conditions as Davesomeran, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account